Q-omics provides the consensus-scored ZNF613 profile across patient tissues and cancer cell-line models. ZNF613 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ZNF613 is differentially expressed in 15, with the highest sampling consensus in KICH. Additionally, ZNF613 RNA expression shows 20,333 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, KICH, and UVM as cancer lineages where ZNF613 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF613 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF613 survival associations across molecular data types. ZNF613 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF613 RNA expression–survival associations across cancer types. High ZNF613 expression shows unfavorable associations in LGG, LUSC, LIHC and ESCA, but favorable associations in KIRC and BLCA. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for ZNF613 RNA expression.
This table summarizes ZNF613 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for ZNF613. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF613 shows lower tumor expression in KICH, THCA, READ and KIRP and higher tumor expression in LIHC and BRCA. The KICH box plot shows higher ZNF613 RNA expression in normal versus tumor tissue (log2 FC = −1.132, t-test p < 0.001).
This table shows molecular features associated with ZNF613 in patient tissues and cancer cell lines. In patient samples, ZNF613 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF613 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in BREAST and BLOOD_Leukemia.
